Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AS1404 with carboplatin and paclitaxel in platinum-sensitive recurrent ovarian epithelial cancer
2004-004375-11Phase 2Completed
- Sponsor
- Antisoma
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vadimezan in epithelial ovarian cancer (EOC) (2 arms), sponsored by Antisoma. Primary endpoints: Tumor response rate and Time to progression. Started Feb 2005; status: completed.
02
Drugs
vadimezan
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2004-004375-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004375-11.